All News

6 May 2010

BioInvent and ThromboGenics Announce Positive Topline Results from Phase II VTE Prophylaxis Study with Anti-Factor VIII (TB-402)Antibodies

6 May 2010

Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE AntibodyAntibodies

3 May 2010

Bristol-Myers Squibb Receives Complete Response Letter from FDA for BelataceptAntibodies

2 May 2010

New Efficacy Data Shows Cimzia(R) (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn’s Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDWAntibodies

27 April 2010

BioSante Pharmaceuticals Enters Option Agreement to its 2A/Furin Antibody Expression TechnologyAntibodies

26 April 2010

TRACON Announces Start of Phase 1/2 Trial of TRC105 Antibody Therapy for Prostate CancerAntibodies

26 April 2010

Symphogen Announces Publication in Molecular Biotechnology of Sympress II Production System Allowing Single-Batch Recombinant Polyclonal Antibody ManufacturingAntibodies

26 April 2010

RoACTEMRA recommended for approval in Europe for the reduction of joint damage and improvement in physical function in rheumatoid arthritisAntibodies

22 April 2010

Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for BYDUREON(TM)Antibodies

22 April 2010

Genentech Submits Supplemental Application to FDA for Herceptin in Advanced HER2-Positive Stomach CancerAntibodies

22 April 2010

Biotie to continue development of and maintain global rights to BTT-1023, its novel VAP-1 antibody for inflammatory diseaseAntibodies

21 April 2010

Immunomedics Develops Potent Immunotoxins Against Solid and Liquid TumorsAntibodies

21 April 2010

AVEO Pharmaceuticals’ Selective Anti-Notch1 Monoclonal Antibody Exhibits Potent Notch1 Inhibitory ActivityAntibodies

21 April 2010

Seattle Genetics and Agensys, an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACRAntibodies

21 April 2010

Genmab Announces Pipeline and Technology UpdateAntibodies

20 April 2010

Seattle Genetics to Receive $9.5 Million Payment from Genentech to Extend Antibody-Drug Conjugate CollaborationAntibodies

20 April 2010

Phase III study evaluating ocrelizumab in patients with rheumatoid arthritis meets primary endpointAntibodies

20 April 2010

Alexion Completes Enrollment in All Four Clinical Trials of Soliris (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)Antibodies

20 April 2010

Human Genome Sciences and GlaxoSmithKline Announce Topline 76-Week Results of Phase 3 Trial of BENLYSTA in Systemic Lupus ErythematosusAntibodies

19 April 2010

Amgen Preclinical Study Demonstrated Anti-Tumor Activity in Mammary Tumor ModelAntibodies

19 April 2010

Immunomedics Develops Novel Immunoconjugate for Targeted Delivery of siRNAs to Solid CancersAntibodies

19 April 2010

GlaxoSmithKline receives conditional marketing authorisation in the EU for Arzerra (ofatumumab)Antibodies

15 April 2010

Circadians VGX-100 Significantly Inhibits Tumour Growth in Animal Models of Human CancerAntibodies

15 April 2010

Kenta Biotech Reports 100% Survival with Panobacumab in Life-Threatening Hospital-Acquired PneumoniaAntibodies

15 April 2010

New Study Shows Combining Peregrine’s Bavituximab With an Apoptosis-Inducing Agent Can Eradicate Tumors in a Model of Advanced Breast CancerAntibodies

14 April 2010

Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically-Active DiseaseAntibodies

14 April 2010

AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody ProgramAntibodies

13 April 2010

Baxter and New York-Presbyterian/Weill Cornell Announce 18-Month Data from Phase II Study of GAMMAGARD in Patients with Alzheimer’s DiseaseAntibodies

12 April 2010

Overcoming resistance – new options for the treatment of ovarian cancerAntibodies

8 April 2010

Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin LymphomaAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Report Package: Claudin 18.2-Targeted Immunotherapeutics

B7-H4 Targeted Antibody Therapy Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Report Package: “Drug the Undruggable” Technologies

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics